Emotion aside, it was a pretty good 4C.
Nice organic growth, don't care much for their last acqusition though, another majority ARR SaaS business would be preferable otherwise I'd rather they just keep the cash reserves for growing the business in-house.
Trading at under 2x rev multiplier with a majority in ARR, it deserves a bit of a premium compared to TNT (I think between 2.5- 3x rev multiplier last I checked) on that alone. I'd expect at least 4x rev upon breakeven this year but the market macros haven't been ideal.
- Forums
- ASX - By Stock
- EXT
- Ann: Appendix 4C and Activities Report
Ann: Appendix 4C and Activities Report, page-14
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EXT (ASX) to my watchlist
|
|||||
Last
0.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.08M |
Open | High | Low | Value | Volume |
0.9¢ | 1.0¢ | 0.9¢ | $52.96K | 5.716M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 708194 | 0.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.0¢ | 7745064 | 14 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 708194 | 0.009 |
10 | 6523057 | 0.008 |
10 | 4306019 | 0.007 |
5 | 1618942 | 0.006 |
3 | 5500000 | 0.005 |
Price($) | Vol. | No. |
---|---|---|
0.010 | 7745064 | 14 |
0.011 | 5248150 | 6 |
0.012 | 5938361 | 5 |
0.013 | 10099423 | 3 |
0.014 | 15131428 | 3 |
Last trade - 15.57pm 15/07/2024 (20 minute delay) ? |
Featured News
EXT (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online